Nasdaq · Healthcare

NEKTAR THERAPEUTICS (NKTR)

As-reported financials and recent SEC filings for NEKTAR THERAPEUTICS, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$55.2M

Net income

$-164.1M

Net margin

—

Diluted EPS

$-9.73

ROE

-182.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$55.2M	$98.4M	$90.1M	$92.1M	$101.9M
Gross profit	—	$67.7M	$56.4M	$70.4M	$77.0M
Operating income	$-140.1M	$-105.2M	$-263.7M	$-376.2M	$-446.1M
Net income	$-164.1M	$-119.0M	$-276.1M	$-368.2M	$-523.8M
Diluted EPS	$-9.73	$-8.68	$-20.30	$-27.58	$-40.04

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

1442026-06-30

42026-06-18

1442026-06-17

42026-06-17

1442026-06-16

1442026-06-15

8-K2026-06-05

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on NKTR

Search NEKTAR THERAPEUTICS’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.